Literature DB >> 17324339

Matrix metalloprotease-9 in cerebrospinal fluid correlates with disease activity in lymphomatous meningitis.

Eric T Wong1, Diana Lee, Angela Tam, Shiva Gautam, Julian K Wu.   

Abstract

PURPOSE: The detection of lymphoma cells in cerebrospinal fluid (CSF) as a means to diagnose lymphomatous meningitis is problematic due to its low sensitivity. We hypothesize that matrix metalloproteases (MMPs) would be important in lymphomatous meningitis because lymphoma cells may produce MMPs for brain invasion and angiogenesis. PATIENTS AND METHODS: Twentynine samples of CSF collected longitudinally from 5 patients receiving treatments for primary or metastatic CNS lymphomas were retrospectively analyzed by zymography. Cerebrospinal fluid cytology was correlated with levels of total protein, glucose, MMP-2, MMP-9, activated MMP-9, and 130 kDa MMP.
RESULTS: Increased CSF white blood cells (65 +/- 32 cells/microL vs. 9 +/- 8 cells/microL; P = 0.03) and MMP-9 (12.108 +/- 2.675 vs. 9.359 +/- 1.936; P = 0.02) had a strong correlation with abnormal CSF cytology. In addition, we observed that activated MMP-9 would appear and disappear depending on disease activity. Although there was nearly a 4-fold increase of mean activated MMP-9 in CSF samples with abnormal cytology findings when compared with negative cytology findings, the correlation did not reach statistical significance (1.382 +/- 0.76 vs. 0.389 +/- 0.155; P = 0.17).
CONCLUSION: Matrix metalloprotease-9 correlated strongly with lymphomatous meningitis, but MMP-2, activated MMP-2, activated MMP-9, and 130-kDa MMP did not.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17324339     DOI: 10.3816/CLM.2007.n.007

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma        ISSN: 1557-9190


  3 in total

1.  YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma.

Authors:  Andreas F Hottinger; Fabio M Iwamoto; Sasan Karimi; Elyn Riedel; Jocelynn Dantis; Joseph Park; Katherine S Panageas; Andrew B Lassman; Lauren E Abrey; Martin Fleisher; Eric C Holland; Lisa M DeAngelis; Adília Hormigo
Journal:  Ann Neurol       Date:  2011-03-09       Impact factor: 10.422

2.  A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: a Pediatric Brain Tumor Consortium study.

Authors:  Susan M Blaney; Michael Tagen; Arzu Onar-Thomas; Stacey L Berg; Sri Gururangan; Kathleen Scorsone; Jack Su; Stewart Goldman; Mark W Kieran; Larry Kun; Jim Boyett; Clinton Stewart
Journal:  Pediatr Blood Cancer       Date:  2012-09-21       Impact factor: 3.167

3.  Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas.

Authors:  Eric T Wong; David Alsop; Diana Lee; Angela Tam; Loretta Barron; Julianne Bloom; Shiva Gautam; Julian K Wu
Journal:  Cerebrospinal Fluid Res       Date:  2008-01-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.